Navigation Links
Therapeutic DNA Vaccine Company Inovio Biomedical Reports Second Quarter 2008 Financial Results
Date:8/7/2008

vestment advisor informed us that decreased market liquidity for this type of security caused the valuation of these investments to fall below par. At June 30, 2008, we recorded on our consolidated balance sheet an unrealized loss of $1.1 million on these investments and reclassified $12.5 million as a non-current asset.

These securities retain the AAA/AA ratings they had when we purchased them, and have yielded uninterrupted interest payments that we receive on a monthly basis directly from the issuers. The lack of liquidity may require us to hold the ARSs until they are redeemed by the issuer or to maturity, but we believe the decline in their liquidity and fair value is temporary. We expect that liquidity of these investments is not required to fund our operations during the next twelve months. The Company anticipates receiving approval of and executing a $5.0 million line of credit from its investment advisor in the third quarter, secured by the ARS, to provide additional working capital.

Corporate Update

The operational highlights for the second quarter included further positive interim results reported by our partners from ongoing DNA vaccine clinical studies. A summary of these results follows, covering R&D and clinical studies using Inovio's electroporation delivery technology. More details can be found in the news release section of Inovio's website.

The University of Southampton presented interim data from its phase I/II clinical study of an experimental DNA-based prostate cancer vaccine, indicating that the combination of this DNA vaccine and electroporation DNA delivery was safe and well-tolerated. Patients treated using electroporation displayed higher levels of antibody and cellular immune responses. Data from preclinical studies performed in collaboration with scientists at Beth Israel Deaconess Medical Center (BIDMC) demonstrated a 77-fold increase in dendritic cells at the site of administration of a D
'/>"/>

Source: PRWeb
Copyright©2008 Vocus, Inc.
All rights reserved  

Page: 1 2 3 4 5 6 7 8 9 10

Related medicine news :

1. Stiefel Laboratories Completes Acquisition of Barrier Therapeutics
2. Nektar Therapeutics Announces Second Quarter 2008 Results
3. Nektar Therapeutics Names Randall Moreadith, M.D., Ph.D. Senior Vice President, Drug Development and Chief Development Officer
4. InteKrin Therapeutics Announces $20 Million Series C Financing
5. Transition Therapeutics Announces No Material Change
6. Halozyme Therapeutics to Hold Pipeline Update Conference Call on August 8
7. DIA/AAPS Co-Sponsored Conference to Examine the Immunogenicity of Therapeutic Proteins
8. Cell Therapeutics, Inc. Announces $12 Million Equity Line of Credit
9. Stiefel Laboratories, Inc. Announces Expiration of Hart-Scott-Rodino Waiting Period Relating to its Proposal to Acquire Barrier Therapeutics, Inc.
10. Neurotherapeutics presents special issue on new treatments for Alzheimers disease
11. Horizon Therapeutics Names Timothy P. Walbert as President and CEO
Post Your Comments:
*Name:
*Comment:
*Email:
Related Image:
 Therapeutic DNA Vaccine Company Inovio Biomedical Reports Second Quarter 2008 Financial Results 
(Date:7/30/2014)... (PRWEB) July 30, 2014 Good ... featured in an upcoming episode of Innovations with ... Discovery Channel. Dates and show times TBA. , ... Good Neighbor Community Services’ vision to redefine the ... individualized and dynamic services. Through passion, innovation, determination, ...
(Date:7/30/2014)... Volunteers from the Church of Scientology of Denmark ... with massive distribution of Truth About Drugs ... on Strøget, the famous Copenhagen walking street. Popular ... its ambiance, some quarter of a million people stroll ... , These activities are part of a coordinating effort ...
(Date:7/30/2014)... MA (PRWEB) July 30, 2014 ... of authentication, access management and secure communications solutions ... Imprivata OneSign ® is the most widely selected ... McKesson Paragon or Horizon electronic medical records (EMR) ... increase of about 11 percent in the last ...
(Date:7/30/2014)... (July 30, 2014) The phrase "we caught it early" ... in the midst of a cancer diagnosis. Combating cancer ... to a certain part of the body, gives patients ... breast, skin, colon, prostate and other forms of cancer ... health care providers recommend cancer screenings as a precautionary ...
(Date:7/30/2014)... Atlanta, Georgia (PRWEB) July 30, 2014 ... Business and Technology Alliance of TAG (B&TA), today issued ... 2014 TAG Excalibur Awards. , Interested companies have until ... program after which, Semi-Finalists will be selected by the ... be required to meet with the judges for interviewing ...
Breaking Medicine News(10 mins):Health News:Good Neighbor Community Services to be Featured in an Upcoming Episode of Innovations With Ed Begley, Jr. 2Health News:Imprivata Achieves 51 Percent Single Sign-on Market Share Amongst U.S. Hospitals Using McKesson Paragon or Horizon EMR Systems, According to HIMSS Analytics 2Health News:UK psychologist creates patient tool to assist with lung cancer screening decision 2Health News:UK psychologist creates patient tool to assist with lung cancer screening decision 3Health News:Last Call for TAG 2014 Excalibur Awards Nominations and Applications 2Health News:Last Call for TAG 2014 Excalibur Awards Nominations and Applications 3
... forget: improving memory in Alzheimer disease mice , ... in memory formation, has been linked to Alzheimer disease. ... have now shown that two different drugs that inhibit ... Alzheimer disease (APP/PS1 mice), leading them to suggest drugs ...
... USA, Inc. announced the signing of a Memorandum of Understanding signifying ... Spray, an all natural, capsaicin-based product for fast relief from allergy ... ... Washington, DC, and Newtown, CT (PRWEB) July 1, 2008 -- ...
... Minn., July 1 Howard Epstein, M.D. has ... medical director for commercial,operations and clinical design. In ... supporting case review and clinician consultation for,integrated health ... Design area, serve as a liaison to Blue ...
... The U.S.,Agency for International Development (USAID) awarded a ... HIV/AIDS in Ethiopia. The program will,provide youth access to ... existing care and prevention programs in five,underserved communities in ... build community networks by means of youth-led volunteer services. ...
... NEW YORK (July 1, 2008) -- Women may ... (CV) drug-treatments for enlarged heart, according to NewYork-Presbyterian ... first time, researchers have uncovered that women derive ... high-blood-pressure-lowering drugs -- losartan and atenolol -- for ...
... toll in outbreak reaches 869, probe expands to include ... 1 (HealthDay News) -- With the number of people ... 869, with 107 hospitalizations, U.S. officials acknowledged Tuesday that ... the contaminant. , The U.S. Food and Drug Administration ...
Cached Medicine News:Health News:JCI online early table of contents: July 1, 2008 2Health News:JCI online early table of contents: July 1, 2008 3Health News:JCI online early table of contents: July 1, 2008 4Health News:JCI online early table of contents: July 1, 2008 5Health News:JCI online early table of contents: July 1, 2008 6Health News:SINOL USA, Inc. and Strategic Pharmaceutical Advisors, Inc. to Enter a Marketing Agreement for SINOL Nasal Spray 2Health News:USAID Announces Youth-Focused HIV/AIDS Programs in Ethiopia 2Health News:Gender differences and heart disease 2Health News:U.S. Officials Stymied in Salmonella Search 2Health News:U.S. Officials Stymied in Salmonella Search 3Health News:U.S. Officials Stymied in Salmonella Search 4
(Date:7/30/2014)... LAS VEGAS , July 30, 2014  DigiPath, ... provider that is expanding into the cannabis testing and ... development in its business and affairs not previously disclosed ... for the recent unusual market action. "We ... securities over the last three trading days," said ...
(Date:7/30/2014)... /PRNewswire-iReach/ -- This is a professional and in-depth ... (CAS 9041-08-1) & calcium (CAS 37270-89-6) industry. The ... sodium (CAS 9041-08-1) & calcium (CAS 37270-89-6) including ... then explores global and China,s top manufacturers of ... listing their product specification, capacity, production value, cost, ...
(Date:7/30/2014)... VILLAGE, Nev. , July 30, 2014  PDL ... announced that company management will participate in the Jefferies ... Boston , Massachusetts. The conference will occur on August ... About PDL BioPharma, Inc. PDL BioPharma manages ... of its Queen et al. antibody humanization patents and ...
Breaking Medicine Technology:DigiPath No New Corporate Developments 2Heparin Sodium & Calcium Industry for Global and Chinese Markets Forecast to 2019 2Heparin Sodium & Calcium Industry for Global and Chinese Markets Forecast to 2019 3Heparin Sodium & Calcium Industry for Global and Chinese Markets Forecast to 2019 4Heparin Sodium & Calcium Industry for Global and Chinese Markets Forecast to 2019 5PDL BioPharma to Participate in Jefferies 2014 Boston Healthcare Summit 2
... Oct. 26, 2011 Reportlinker.com ... research report is available in ... Early Stage Drug Safety Strategies ... towards achieving clinical success ...
... Oct. 26, 2011 Reportlinker.com announces ... is available in its catalogue: ... Pharmaceutical R&D: Company strategies, emerging markets ... http://www.reportlinker.com/p0114851/Key-Trends-in-Offshoring-Pharmaceutical-RD-Company-strategies-emerging-markets-and-impact-on-ROI.html#utm_source=prnewswire&utm_medium=pr&utm_campaign=Drug_Discovery_and_Development ...
Cached Medicine Technology:Early Stage Drug Safety Strategies and Risk Management: Maximizing opportunities towards achieving clinical success 2Early Stage Drug Safety Strategies and Risk Management: Maximizing opportunities towards achieving clinical success 3Early Stage Drug Safety Strategies and Risk Management: Maximizing opportunities towards achieving clinical success 4Early Stage Drug Safety Strategies and Risk Management: Maximizing opportunities towards achieving clinical success 5Early Stage Drug Safety Strategies and Risk Management: Maximizing opportunities towards achieving clinical success 6Early Stage Drug Safety Strategies and Risk Management: Maximizing opportunities towards achieving clinical success 7Early Stage Drug Safety Strategies and Risk Management: Maximizing opportunities towards achieving clinical success 8Key Trends in Offshoring Pharmaceutical R&D: Company Strategies, Emerging Markets and Impact on ROI 2Key Trends in Offshoring Pharmaceutical R&D: Company Strategies, Emerging Markets and Impact on ROI 3Key Trends in Offshoring Pharmaceutical R&D: Company Strategies, Emerging Markets and Impact on ROI 4Key Trends in Offshoring Pharmaceutical R&D: Company Strategies, Emerging Markets and Impact on ROI 5Key Trends in Offshoring Pharmaceutical R&D: Company Strategies, Emerging Markets and Impact on ROI 6Key Trends in Offshoring Pharmaceutical R&D: Company Strategies, Emerging Markets and Impact on ROI 7Key Trends in Offshoring Pharmaceutical R&D: Company Strategies, Emerging Markets and Impact on ROI 8Key Trends in Offshoring Pharmaceutical R&D: Company Strategies, Emerging Markets and Impact on ROI 9
... Laboratories is a national reference laboratory and ... and development. ARUP offers an extensive test ... tests in clinical and anatomic pathology. Owned ... clients include more than half of the ...
... national reference laboratory and a worldwide leader ... offers an extensive test menu of highly ... and anatomic pathology. Owned by the University ... than half of the nation's university teaching ...
... is a national reference laboratory and a ... development. ARUP offers an extensive test menu ... in clinical and anatomic pathology. Owned by ... include more than half of the nation's ...
... national reference laboratory and a worldwide leader ... offers an extensive test menu of highly ... and anatomic pathology. Owned by the University ... than half of the nation's university teaching ...
Medicine Products: